Positive sentinel lymph node biopsy predicts the number of metastatic axillary nodes of breast cancer

被引：4

作者：

Takei, Hiroyuki ^{[1
]}

Kurosumi, Masafumi ^{[2
]}

Yoshida, Takashi ^{[1
]}

Ninomiya, Jun ^{[1
]}

Ishikawa, Yuko ^{[1
]}

Hayashi, Yuji ^{[1
]}

Tozuka, Katsunori ^{[1
]}

Asakawa, Hideki ^{[1
]}

Oba, Hanako ^{[2
]}

Inoue, Kenichi ^{[3
]}

Tabei, Toshio ^{[3
]}

机构：

[1] Saitama Canc Ctr, Div Breast Surg, Ina, Saitama 3620806, Japan

[2] Saitama Canc Ctr, Dept Pathol, Ina, Saitama 3620806, Japan

[3] Saitama Canc Ctr, Div Breast Oncol, Ina, Saitama 3620806, Japan

来源：

BREAST | 2009年 / 18卷 / 04期

关键词：

Breast cancer; Sentinel lymph node biopsy; Number of metastatic axillary nodes; CARCINOMA; DISSECTION; RESECTION; TRIAL;

D O I：

10.1016/j.breast.2009.05.007

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

It remains to be clarified whether a positive sentinel lymph node biopsy (SLNB) can predict the number of metastatic axillary nodes. This study examined a consecutive series of women with unilateral invasive breast cancer who underwent axillary lymph node dissection after an intra-operative positive SLNB. The numbers of positive and negative sentinel lymph nodes (SLNs) were analyzed for a likelihood of pN1a, pN2a, and pN3a diseases as per the UICC TNM classification. Of the 368 study patients, 165 (45%) had one positive SLN and one or more negative SLNs. This result represented the most common combination of positive and negative SLNs. It was also the most predictive indicator (93%) of pN1a disease and the least predictive indicator (7% or 0%) of pN2a or pN3a disease, respectively. The numbers of positive and negative SLNs can predict the number of metastatic axillary nodes in breast cancer patients. (C) 2009 Elsevier Ltd. All rights reserved.

引用

页码：244 / 247

页数：4

共 26 条

[11] Significance and problems of histopathological examination and utility of real-time reverse transcriptase-polymerase chain reaction method for the detection of sentinel lymph node metastasis in breast cancer. [J].

Kurosumi M. ;

Takei H. .

Breast Cancer, 2007, 14 (4) :342-349

[12] Axillary treatment in conservative management of operable breast cancer: Dissection or radiotherapy? Results of a randomized study with 15 years of follow-up [J].

Louis-Sylvestre, C ;

Clough, K ;

Asselain, B ;

Vilcoq, JR ;

Salmon, RJ ;

Campana, F ;

Fourquet, A .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (01) :97-101

[13] American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer [J].

Lyman, GH ;

Giuliano, AE ;

Somerfield, MR ;

Benson, AB ;

Bodurka, DC ;

Burstein, HJ ;

Benson, AB ;

Bodurka, DC ;

Burstein, HJ ;

Cochran, AJ ;

Cody, HS ;

Edge, SB ;

Galper, S ;

Hayman, JA ;

Kim, TY ;

Perkins, CL ;

Podoloff, DA ;

Sivasubramaniam, VH ;

Turner, RR ;

Wahl, R ;

Weaver, DL ;

Wolff, AC ;

Winer, EP .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (30) :7703-7720

[14] Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: The ALMANAC trial [J].

Mansel, RE ;

Fallowfield, L ;

Kissin, M ;

Goyal, A ;

Newcombe, RG ;

Dixon, JM ;

Yiangou, C ;

Horgan, K ;

Bundred, N ;

Monypenny, I ;

England, D ;

Sibbering, M ;

Abdullah, TJ ;

Barr, L ;

Chetty, U ;

Sinnett, DH ;

Fleissig, A ;

Clarke, D ;

Ell, PJ .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2006, 98 (09) :599-609

[15] Clinicopathologic features associated with having four or more metastatic axillary nodes in breast cancer patients with a positive sentinel lymph node [J].

Rivers, AK ;

Griffith, KA ;

Hunt, KK ;

Degnim, AC ;

Sabel, MS ;

Diehl, KM ;

Cimmino, VM ;

Chang, AE ;

Lucas, PC ;

Newman, LA .

ANNALS OF SURGICAL ONCOLOGY, 2006, 13 (01) :36-44

[16] Clinical trials update of the European Organization for Research and Treatment of Cancer Breast Cancer Group [J].

Rutgers, EJT ;

Meijnen, P ;

Bonnefoi, H .

BREAST CANCER RESEARCH, 2004, 6 (04) :165-169

[17] 99mTc-phytate is better than 99mTc-human serum albumin as a radioactive tracer for sentinel lymph node biopsy in breast cancer [J].

Takei, H ;

Suemasu, K ;

Kurosumi, M ;

Ninomiya, J ;

Horii, Y ;

Inoue, K ;

Tabei, TH .

SURGERY TODAY, 2006, 36 (03) :219-224

[18] Current trends of sentinel lymph node biopsy for breast cancer--a surgeon's perspective. [J].

Takei H. ;

Kurosumi M. ;

Yoshida T. ;

Ninomiya J. ;

Hagiwara Y. ;

Kamimura M. ;

Hayashi Y. ;

Tozuka K. ;

Suemasu K. ;

Inoue K. ;

Tabei T. .

Breast Cancer, 2007, 14 (4) :362-370

[19] Recurrence after sentinel lymph node biopsy with or without axillary lymph node dissection in patients with breast cancer. [J].

Takei H. ;

Suemasu K. ;

Kurosumi M. ;

Horii Y. ;

Yoshida T. ;

Ninomiya J. ;

Yoshida M. ;

Hagiwara Y. ;

Kamimura M. ;

Hayashi Y. ;

Inoue K. ;

Tabei T. .

Breast Cancer, 2007, 14 (1) :16-24

[20] Added value of the presence of blue nodes or hot nodes in sentinel lymph node biopsy of breast cancer. [J].

Takei H. ;

Suemasu K. ;

Kurosumi M. ;

Horii Y. ;

Ninomiya J. ;

Kamimura M. ;

Naganuma R. ;

Uchida K. ;

Igarashi K. ;

Inoue K. ;

Tabei T. .

Breast Cancer, 2006, 13 (2) :179-185

← 1 2 3 →